LLY
769.87
+0.76%↑
JNJ
155.03
+1.03%↑
ABBV
189.89
+1.42%↑
NVO
74.74
+3.06%↑
UNH
303.11
+2.59%↑
LLY
769.87
+0.76%↑
JNJ
155.03
+1.03%↑
ABBV
189.89
+1.42%↑
NVO
74.74
+3.06%↑
UNH
303.11
+2.59%↑
LLY
769.87
+0.76%↑
JNJ
155.03
+1.03%↑
ABBV
189.89
+1.42%↑
NVO
74.74
+3.06%↑
UNH
303.11
+2.59%↑
LLY
769.87
+0.76%↑
JNJ
155.03
+1.03%↑
ABBV
189.89
+1.42%↑
NVO
74.74
+3.06%↑
UNH
303.11
+2.59%↑
LLY
769.87
+0.76%↑
JNJ
155.03
+1.03%↑
ABBV
189.89
+1.42%↑
NVO
74.74
+3.06%↑
UNH
303.11
+2.59%↑
24h
Praegune
Min
249.82
Max
257.37
Sissetulek | 153M 1.3M |
---|---|
Müük | -11M 1.1B |
Kasumimarginaal | 0.114 |
Soovitused | Tugev "osta" hinnang |
---|---|
12 kuu keskmine prognoos | +30.42% upside |
Järgmine tulemuste avaldamine | 6. aug 2025 |
---|
Turukapital | 22B |
---|---|
Eelmine avamishind | 255.23 |
Eelmine sulgemishind | 254.35 |
By Acuity
50%
50%
166 / 380 Pingereas Healthcare
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
12. mai 2025, 02:16 UTC
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs
DJ
Loe
29. jaan 2025, 15:59 UTC
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
DJ
Loe
27. nov 2024, 15:22 UTC
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment
DJ
Loe
21. nov 2024, 14:45 UTC
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
DJ
Loe
22. okt 2024, 18:39 UTC
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
DJ
Loe
7. mai 2025, 10:07 UTC
BeiGene Maintains 2025 Expense Guidance of $4.1B to $4.4B >ONC
DJ
Loe
7. mai 2025, 10:06 UTC
BeiGene Backs 2025 Rev $4.9B-$5.3B >ONC
DJ
Loe
7. mai 2025, 10:05 UTC
BeiGene 1Q Net $1.27M >ONC
DJ
Loe
7. mai 2025, 10:04 UTC
BeiGene Says to Rename Company to BeOne Medicines >ONC
DJ
Loe
7. mai 2025, 10:02 UTC
BeiGene 1Q EPS $0.00 >ONC
DJ
Loe
7. mai 2025, 10:02 UTC
BeiGene 1Q Rev Increased 49% >ONC
DJ
Loe
7. mai 2025, 10:00 UTC
BeiGene 1Q Rev $1.12B >ONC
DJ
Loe
27. veebr 2025, 11:07 UTC
BeiGene Sees 2025 Rev $4.9B-$5.3B >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Global BRUKINSA Rev of $828M >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Loss/Shr 11c >ONC
DJ
Loe
27. veebr 2025, 11:06 UTC
BeiGene 4Q Rev $1.13B >ONC
DJ
Loe
12. nov 2024, 11:01 UTC
BeiGene 3Q Loss/Shr 9c >BGNE
DJ
Loe
12. nov 2024, 11:01 UTC
BeiGene 3Q Rev $1B >BGNE
DJ
Loe
7. aug 2024, 10:05 UTC
BeiGene 2Q Loss/Shr $1.15 >BGNE
DJ
Loe
7. aug 2024, 10:04 UTC
BeiGene 2Q Rev $929M >BGNE
DJ
Loe
Hinnamuutus
By TipRanks
12 kuu keskmine prognoos
Keskmine 335.18 USD 30.42%
Kõrge 359.47 USD
Madal 300 USD
Põhineb 9 Wall Streeti analüütiku instrumendi BeOne Medicines Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.
By TipRanks
Tugev "osta" hinnang
9 ratings
8
Osta
1
Hoia
0
Müü
Põhineb 9 analüütiku instrumendi BeOne Medicines Ltd ADR aktsia reitingul - viimase 3 kuu andmed.
By Acuity
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Keskmine
Müügi- ja halduskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Ärikasum
$